The APCCC in Basel, Switzerland: Day 1

So in this series of reports on what happened at the 3rd Advanced Prostate Cancer Consensus Conference (APCCC) in Basel, Switzerland, we will not be trying to get into detail about exactly what data got presented each day. … READ MORE …

Computer modeling, genomics, and prostate cancer prognosis

A newly published paper on the development of prostate cancer in patients of ≤ 55 years of age claims to have shown that

Using a newly-developed computer model, it is now possible to predict the course of the disease in individual patients. … READ MORE …

Understanding the genetics of prostate cancer diagnosis and treatment

For those who are interested in this evolving topic, we recommend listening to Dr. Charles Ryan’s 16-minute-long discussion with Heather Cheng, MD, PhD, entitled “Genetic evaluation and counseling in prostate cancer treatment”. … READ MORE …

Another 63 genetic variants seem to affect risk for diagnosis with prostate cancer

Newly published research in Nature Genetics has reported the identification of yet another 63 new variants in the human genome that increase risk for a diagnosis of prostate cancer in males. This takes the total number of such variants identified to date to something approaching 175. … READ MORE …

FDA approves key genetic/genomic test for cancer mutations

According to reports from the Associated Press and others, some time late last Thursday the  US Food & Drug Administration (FDA) appears to have approved the use of the FoundationOne CDx genetic/genomic test for patients with “advanced or widely spread cancers.” A media release from Foundation Medicine is also available on line. … READ MORE …

Could “single cell genomics” replace Gleason grading in prostate cancer risk evaluation?

According to a study just published in Cancer Research, a completely new technique referred to as “single cell genomics” may be able to improve the accuracy of diagnosis of prostate cancer based on biopsy tissue. … READ MORE …

Understanding genetics, genomics, and their utility in prostate cancer

Our friends at UroToday have just published a perfectly lovely lecture on this topic given by Prof. Lenny Gomella at the recent annual meeting of the Large Urology Group Practice Association (LUGPA). … READ MORE …

More reports from the EAU “Update on Prostate Cancer”

Dr. Zachary Klaassen and UroToday have provided us with four more interesting summaries of presentations by faculty at the European Association for Urology (EAU)’s meeting in Vienna last weekend. … READ MORE …

Genetics, PSA, and steps toward a better prostate cancer risk management strategy

A new analysis of a large data set compiled by Kaiser Permanente suggests that combining PSA data with genetic risk data may offer a much more effective way to assess risk for clinically significant prostate cancer. … READ MORE …

Predicting the future: what Genomic Health isn’t telling us (yet)

A media release issued  yesterday by Genomic Health, Inc., has suggested that the multi-gene Oncotype DX® Genomic Prostate Score™ is a strong predictor of risk for the development of metastasis and prostate cancer death in patients with early-stage prostate cancer. … READ MORE …

What’s happening at the annual EAU meeting in Munich?

So our friends at UroToday have started providing reports on the key presentations that are being given at the annual meeting of the European Association of Urology, being held this year in Munich, Germany. Here are links to some interesting reports … READ MORE …

Pathway Genomics’ Cancer Intercept test has a problem

Earlier this month The “New” Prostate Cancer InfoLink stated that the new liquid biopsy test being touted by Pathways Genomics was of no proven value in the diagnosis of prostate cancer and that we expected the U.S. Food and Drug Administration (FDA) would have some comments on the promotion of this test. We were correct. … READ MORE …

Genetics, genomics, targeted therapy, and “personalized” cancer care

If you are still under the illusion that, simply by identifying the precise structure of the deoxyribonucleic acid (DNA) of patients’ cancer cells, we will be able to develop and target drugs that can eliminate specific cancers (or indeed other disorders) in specific individuals, an article by Sharon Begley on the Reuters.com web site should help to disabuse you. … READ MORE …

Genetics, genomics, and improvements in the management of prostate cancer

Over the past few years we have seen a great deal of discussion of this or that new gene or single nucleotide polymorphism (SNP) or other set of genomic data and the potential of such information to improve the diagnosis or the prognosis of prostate cancer. … READ MORE …